Psoriasis Vulgaris
Conditions
Keywords
Psoriasis Vulgaris, Plaque, Topical, Treatment
Brief summary
The purpose of this study is to determine the efficacy of DD-25, a new topical drug, on plaque Psoriasis Vulgaris. The study will include subjects at plaque stage from 5-20% body area involvement. A total of 30 subjects will be treated with cream application on affected areas twice daily for three weeks.The efficacy of the preparation will be documented by PASI score, Global physician assessment and photos.
Detailed description
Psoriasis Vulgaris remains a widespread clinical entity with chronic outflares and various regimens of treatment, none of them definitive. A new safe and efficacious, external treatment is required for.
Interventions
DRUGDD-25
A topical DD-25 cream at 0.025% concentration.
Sponsors
Fortuderm Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Subject age 18-60 2. Diagnosis of PS by a dermatologist with lesions on arms, legs or trunk 3. Subjects have stable plaque PS, mild to moderate form, Body Surface Area of 5-20%. 4. Subject understood and signed an informed consent form
Exclusion criteria
1. Guttate, erythrodermic, palm-plantar or pustular psoriasis as sole or predominant form of psoriasis. 2. Hypersensitivity to sunlight; history of Lupus, PMLE, or any disease known to be worsened by UV light exposure 3. Pregnancy, breast feeding 4. History of cancer, excluding non-melanoma skin cancer. 5. Patients with history of ischemic heart disease (e.g. angina pectoris, myocardial infarction); cerebrovascular syndromes, peripheral vascular or uncontrolled hypertension. Subjects with known severe hepatic and/or severe renal insufficiency. 6. Any medical condition that, in the opinion of the Investigator, would jeopardize the health of the patient during the course of this study. 7. Systemic treatment with biological therapies with a possible effect on psoriasis vulgaris within 4 months or 5 drug half-lives prior to checkup. 8. Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immuno-suppressants) within the 8-week period prior to randomization. Subjects using within the 8 week period prior to randomization PUVA or Phototherapy. Use of SSRI or MAO inhibitors. 9. Subjects using one of the following TOPICAL drugs for the treatment of PS within 2 weeks prior to randomization: e.g. WHO group I-II corticosteroids, retinoids, Vit. D analogues, immunomodulators, Anthracene derivatives, Salicylic acid. 10. Subjects with current participation in any other interventional clinical or subjects with any concomitant dermatological disorder(s) which might preclude accurate evaluation of the psoriasis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy after 3 weeks as compared to baseline. | 3 weeks | Evaluation of the effectiveness of DD-25 over a period of 3 weeks treatment by analyzing the changes in the Psoriasis Area & Severity Index (PASI) in moderate to mild Plaque Psoriasis patients. Improvement to be assessed by changes in erythema, induration and desquamation as seen on days 0, 10 and 21. |
Secondary
| Measure | Time frame |
|---|---|
| PASI reduction of 50% | 3 weeks |
Countries
Israel
Contacts
Primary ContactAvi Dascalu, M.D., Ph.D.
Outcome results
None listed